ArticleRheumatology and therapy2026
Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL Study.
Article in Rheumatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe present the final results of the CANadian TOfacitinib for Rheumatoid Arthritis observationaL (CANTORAL) study, which investigated tofacitinib effectiveness, safety, and persistence to month (M) 36 in patients with rheumatoid arthritis (RA).
methodsPatients with RA initiating tofacitinib in Canada (October 2017-June 2022) were enrolled in a multicenter, prospective, observational study. Coprimary effectiveness outcomes were Clinical Disease Activity Index (CDAI)-defined low disease activity (LDA) and remission at M6. Secondary and additional outcomes included Disease Activity Score in 28 joints using erythrocyte sedimentation rate/C-reactive protein (DAS28-4[ESR/CRP])-defined LDA and remission, and change from baseline (CFB) in Health Assessment Questionnaire Disability Index (HAQ-DI). Safety was evaluated to M36.
resultsOverall, 505 and 507 patients were included in the effectiveness and safety analysis sets, respectively; 59.2% were biologic disease-modifying antirheumatic drug-naïve, 79.2% were ≥ 50 years, 38.6% were ≥ 65 years, and 56.0% were current/former smokers. 59.6% discontinued the study. LDA/remission rates at M36 were: CDAI, 71.0% (n/N = 66/93)/35.5% (n/N = 33/93); DAS28-4(ESR), 69.6% (n/N = 32/46)/52.2% (n/N = 24/46); DAS28-4(CRP), 79.7% (n/N = 47/59)/66.1% (n/N = 39/59); 66.1% (n/N = 82/124) patients had HAQ-DI CFB ≥ 0.22. Treatment-emergent adverse events (TEAEs), TEAEs of special interest, and deaths were reported in 69.8% (n/N = 354/507), 46.5% (n/N = 236/507), and 1.2% (n/N = 6/507) of patients, respectively. For patients with major adverse cardiovascular events and malignancies (excluding nonmelanoma skin cancer), proportions of current/former smokers and patients ≥ 65 years were higher than in the whole population.
conclusionsTofacitinib provided early and sustained improvement of disease signs and symptoms in patients with RA in Canada. Safety was consistent with the RA clinical program and the established tofacitinib clinical profile. Results were consistent with the interim analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.